This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
VIA AILooking for an interpreter?
Remoto by ProZ.com connects you with an identity-verified interpreter by video or phone in about 60 seconds — 300+ languages, on demand or booked ahead.
Try Remoto »
Member since Jun '12
Working languages:
German to English English (monolingual) German (monolingual)
Client-vendor relationship recorded successfully!
Alexandra Lemonidis has been added to your list of hired vendors.
Freelance translator and/or interpreter, Verified member
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
German to English: Progress in the diagnosis of Alzheimer dementia. General field: Medical Detailed field: Medical: Health Care
Source text - German Auszug aus:
Fortschritte in der Diagnostik der Alzheimer-Demenz.
Fiedler U, Wiltfang J, Peters N, Benninghoff J.
Nervenarzt 2012; 83: 661–73.
[…] Neuere Ergebnisse auf dem Sektor der Biomarkerforschung wurden auch in den Abschnitt zur klinisch apparenten Demenz integriert. Relevant ist hier, dass nicht unbedingt die Störung des Erinnerungsvermögens die Kardinalsymptomatik aus dem Kreis der kognitiven Dysfunktion bilden muss [3]. Allgemein betrachtet gehören Patienten, die bisher einer „wahrscheinlichen (‚probable’) AD“ zugeordnet wurden, auch nach neuer Klassifikation weiter in diese Gruppe, während teilweise Patienten, die bisher unter „mögliche (‚possible’) AD“ fielen, reevaluiert werden müssen. Dies ist auf zusätzliche Biomarkerbefunde und erweiterte klinische Befunde zurückzuführen, die nun zur Erhärtung der diagnostischen Sicherheit integriert wurden.
Wie auch bei den bisher genannten AD-Erkrankungsphasen unterscheiden die Autoren zwei Zielgruppen in der revidierten Fassung der diagnostischen Forschungskriterien: Einerseits richtet sich der überarbeitete Kriterienkatalog an Ärzte ohne Zugang zu ausführlichen neuropsychologischen Testungen, MRT, Nuklearmedizin oder einem neurochemischen Labor mit Expertise auf dem Gebiet der Liquoranalytik. Andererseits wird von klinischen Zentren, die diese zusätzliche biomarker-abhängige Validierung der Demenz-diagnose bereitstellen können, von den Autoren der überarbeiteten diagnostischen Forschungskriterien gefordert, zukünftig die Standardisierung und Qualitätskontrolle dieser biomarkergeleiteten Diagnostik weiter zu verbessern.
Translation - English Excerpt from:
Progress in the diagnosis of Alzheimer dementia.
Fiedler U, Wiltfang J, Peters N, Benninghoff J.
Nervenarzt 2012; 83:661–73.
[…] More recent results from the area of biomarker research were also integrated in the section on clinically apparent dementia. Here, it is important to note that memory impairment does not necessarily have to be the core symptom among the group of cognitive deficits [3]. In general, patients who up until now have been categorized as having “probable AD” will remain in this group, even after renewed classification; whereas some of the patients who previously fell into the category of “possible AD” will require re-evaluation. This is a consequence of the additional biomarker evidence and expanded clinical findings that have now been integrated to improve diagnostic reliability.
As they do for the phases of AD disease mentioned above, the authors also identify two target groups in the revised version of the diagnostic research criteria: On the one hand, the re-worked catalogue of criteria targets those physicians, who have no access to extensive neuropsychological tests, MRT, nuclear medicine, or a neurochemistry laboratory with expertise in the area of cerebrospinal fluid analysis. On the other hand, where clinical centres are able to provide this additional biomarker-dependent validation of a dementia diagnosis, the authors of the revised diagnostic research criteria demand further improvement in the standardization and quality control of biomarker-led diagnosis in the future.
More
Less
Translation education
Other - Chartered Institute of Linguists (London)
Experience
Years of experience: 13. Registered at ProZ.com: Jun 2012. Became a member: Jun 2012.
Experience, Qualifications and Skills As a native English speaker, my school education in Munich, Germany (Abitur, 1988) and my training for a diploma in translation from the London-based Chartered Institute of Linguists (CIOL) (distinctions awarded for literature and science papers, 2002) have given me an excellent grasp of the German language. My degree in immunology (BSc, 1st class, University of Edinburgh, 1992) and my long-standing writing career in medical communications (1996–2023) have trained me to understand complex scientific materials, pay scrupulous attention to detail, and handle language with creativity and flair. Together, these qualifications and skills enable me to create elegant translations that specifically target the desired readership. Translation Services I offer a competent and reliable translation service in a variety of areas, in particular medicine and biosciences: Main areas of expertise Oncology (especially breast and liver cancer); stroke medicine (especially thrombolytic agents); sleep medicine (including sleep apnoea); skin disorders (especially psoriasis); immunology. Additional areas of knowledge Diabetes; silver smithing; gardening. Type of copy Original research papers & abstracts; scientific reviews & reports; meeting reports; academic posters & slide presentations; product monographs; newsletters & leave pieces. Nature of copy Academic/scientific; educational; promotional. For other types of content or copy, I would be happy to provide an initial assessment and quote.
Member since Jun '12
Expertise 